Expression of Survivin in Non-Small Cell Lung Carcinoma: Relationship to Tumor Biology and Prognosis in Surgically Treated Patients.
- Author:
Min Jung JUNG
1
;
Bong Kwon CHUN
Author Information
1. Department of Pathology, College of Medicine, Kosin University, Busan, Korea. bk1000@empal.com
- Publication Type:Original Article
- Keywords:
Survivin protein;
p53 protein;
Cell proliferation;
Carcinoma;
non-small-cell lung
- MeSH:
Adult;
Biology*;
Carcinogenesis;
Cell Proliferation;
Gene Expression;
Humans;
Incidence;
Lung*;
Lymph Nodes;
Neoplasm Metastasis;
Prevalence;
Prognosis*;
Up-Regulation
- From:Korean Journal of Pathology
2005;39(3):151-157
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Survivin, a novel member of inhibitor-of-apoptosis, is undetectable in most terminally differentiated nonproliferative adult tissue, but is overexpressed in some human malignancies. The survivin gene expression is repressed by binding of wild-type p53 with the survivin promotor. In this study, we investigated the prevalence of survivin expression, its association with p53 overexpression and proliferative index, and clinicopathological significance in non-small cell lung carcinomas (NSCLC). METHODS: Immunohistochemical stainings were performed in 59 cases of primary NSCLC for survivin, p53 and Ki-67. Correlations between the survivin expression, p53 overexpression and Ki-67 labeling index were analyzed. RESULTS: Survivin expression was detected in 47 carcinomas (80%) with nuclear immunoreactivity (56%). Survivin nuclear immunoreactivity revealed significantly worse prognosis in NSCLC patients (p=0.003), and correlated with lymph node metastasis (p=0.014), lymphovascular invasion (p=0.032), p53 overexpression, and Ki-67 labeling index (KI 24.2 +/- 6.9, p=0.045). Survivin expression was not correlated with histological type and pT status. CONCLUSIONS: High incidence of survivin overexpression in NSCLC suggests that survivin is involved in lung carcinogenesis, and nuclear expression of survivin can be used as a poor prognostic predictor in NSCLC patients. Expression of mutant p53 seems to be a possible mechanism of survivin up-regulation in NSCLC.
